micro-community-banner
 
  • Saved
What is the Future of Diagnostics in Heart Failure? - PubMed

What is the Future of Diagnostics in Heart Failure? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39998145/

Heart failure (HF) is a common and malignant condition. Disease-modifying therapies are available, with early diagnosis being crucial as these therapies modify risk within weeks of commencement. A higher proportion...

Early diagnosis of heart failure (HF) is critical for effective treatment. AI-driven diagnostic advancements, especially in echocardiography, may help reduce diagnosis delays and improve outcomes, particularly in community settings.

  • Saved

This review analyzes ACC heart failure treatment guidelines, highlighting challenges in HFmrEF and HFpEF management, recent clinical trials, and the need for improved coordination among clinicians to optimize pharmacotherapy.

Comprehensive review of the heart failure management guidelines presented by the American College of Cardiology and the current supporting evidence - PubMed

Comprehensive review of the heart failure management guidelines presented by the American College of Cardiology and the current supporting evidence - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39054773/

The current guidelines for managing HFrEF have been consistent, but there is limited consensus on treating HFmrEF and HFpEF. Large RCTs have provided compelling evidence supporting the use of the...

  • Saved
Is the triglyceride-glucose index ready for cardiovascular risk assessment? - PubMed

Is the triglyceride-glucose index ready for cardiovascular risk assessment? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39939250/

The index is strongly associated with cardiovascular mortality and cardiovascular risk factors. However, some gaps need to be addressed.

This review examines the triglyceride-glucose index as a promising, simpler alternative for assessing insulin resistance and cardiovascular risk, highlighting its strong associations, limitations, and future research directions.

  • Saved
Reducing Hospitalizations and Improving Patient Outcomes in Heart Failure Management

Heart failure (HF) remains a leading cause of morbidity, affecting an estimated 6 million adults in the U.S. The clinical benefits of guideline-directed medical therapy (GDMT) in heart failure, particularly in patients with reduced ejection fraction (HFrEF), are well-documented, with studies showing a mortality reduction of over 70%. Despite this, GDMT remains underutilized, with significant gaps in implementation across patient care settings, especially in outpatient care.

Recent data show that while hospital-based interventions effectively optimize GDMT during acute HF exacerbations, challenges persist in outpatient settings in ensuring sustained GDMT optimization. Fewer than 20% of outpatients with HFrEF achieve target β-blocker doses, and only 10% undergo dose adjustments over the following year. These gaps highlight the critical need to improve GDMT implementation across care settings.

Innovative strategies, including digital health technologies, are addressing these challenges by empowering patients and facilitating continuous engagement. Tools like wearable devices, telemedicine platforms, and educational apps have demonstrated the potential to improve medication adherence and GDMT optimization. For instance, the EPIC-HF trial demonstrated that leveraging digital solutions combining patient education and engagement tools enhances outpatient care, reduces hospitalizations, and improves long-term outcomes.

What are the primary barriers to optimizing GDMT in outpatient heart failure management?

What practical steps can HCPs take to ensure early medication uptitration in outpatient settings?

  • March 15, 2025
    The biggest barrier is the reluctance of insurance providers to cover state of the art medical care : ARNI, sglt2 inhibitors. Additionally, the out of pocket costs are Unsurmountable Show More
  • March 11, 2025
    I believe the biggest barrier is related to the cost of the medication. The generics are easy to prescribe for patients to get however, the SGLT2i and the ARNI’s usually Show More
Profile Image
  • Saved
Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review - PubMed

Smartwatches in the assessment of heart failure patients in epidemiology and pathophysiology studies: A scoping review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39905203/

A limited number of studies with smartwatches (SWs) investigated their potential in the field of heart failure (HF). The aim of this scoping review is to understand the extent of...

Smartwatches show potential for heart failure management by providing objective activity data, aiding NYHA classification, and supporting outpatient care. Accuracy varies by metric, but patient adherence and cardiologist acceptance are promising.